Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Gilead gives up on $4.9B antibody magrolimab
Gilead dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline.
Nick Paul Taylor
Apr 26, 2024 10:04am
AstraZeneca drops GOLDILOX and the porcupine in R&D update
Apr 25, 2024 3:24am
Sanofi crosses Sjögren's off $5B drug's hit list after phase 2
Apr 25, 2024 2:35am
Big Pharma ROI for drug R&D saw surprise rebound in 2023: report
Apr 25, 2024 12:01am
Roche's R&D rethink hits 20% of molecules as cancer drugs axed
Apr 24, 2024 4:27am
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Apr 16, 2024 10:05am